{"id":"W2568802220","doi":"10.1016/j.jtho.2016.11.238","title":"OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Tolerability; Internal medicine; Adverse effect; Oncology; Ipilimumab; Docetaxel; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Population; Progression-free survival; Chemotherapy; Phases of clinical research; Immunotherapy; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007616709,0.0003885656,0.001055943,0.0002682907,0.000325622,0.00123884,0.0005028196,0.0007960469,0.001471983],"category_scores_gemma":[0.00123447,0.0002096975,0.002367966,0.0004237183,0.000356135,0.0009988348,0.0004690929,0.001610817,0.0003152887],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001052871,"about_ca_system_score_gemma":0.0009139093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002911544,"about_ca_topic_score_gemma":0.006148448,"domain_scores_codex":[0.9996661,0.00006473154,0.00002516247,0.00007626956,0.00004039265,0.0001273308],"domain_scores_gemma":[0.9991546,0.0001744941,0.0002317032,0.00005508202,0.00006077709,0.0003234285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1697351,0.003483028,0.6666058,0.0009713069,0.007427735,0.001108413,0.0002400695,0.002759441,0.003928895,0.0003806957,0.007407761,0.1359518],"study_design_scores_gemma":[0.01137847,0.02929132,0.9413991,0.0002711121,0.00738092,0.001004407,0.0004757802,0.002517611,0.0007040999,0.0005365789,0.004953789,0.00008676924],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889202,0.008390615,0.00006165893,0.0003585539,0.0001791753,0.00002739085,0.0008772666,0.00001185421,0.001173268],"genre_scores_gemma":[0.9946308,0.001910055,0.00006478285,0.000438255,0.0001912219,0.00002442087,0.002116254,0.000004255577,0.0006198433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002911544,"threshold_uncertainty_score":0.00763917,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02547052818251097,"score_gpt":0.3758445914173529,"score_spread":0.3503740632348419,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}